Kannalife Sciences, Inc., now known as Neuropathix, Inc., is a leading bio-pharmaceutical and phyto-medical company dedicated to researching and developing groundbreaking therapeutic agents. Their goal is to combat oxidative stress, act as immuno-modulators, and provide neuroprotectants. They hold an exclusive license with the National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of U.

S. Patent 6,630,507, known as the 507 Patent. The company's research and development efforts are focused on a target drug candidate to treat Hepatic Encephalopathy (HE), a disease linked to oxidative stress that affects cognitive and behavioral functions.

Their commitment to innovation and scientific excellence drives the development of novel cannabinoid therapeutics to improve patient care. Through extensive pre-clinical research, Kannalife has discovered proprietary CBD-like molecules that are up to 200 times more potent, 10 times more bioavailable, 5 times safer, and 1000 times more effective than CBD. With their advanced product platform and expertise, Kannalife is revolutionizing the field of cannabinoid therapeutics and paving the way for new treatment options